Biliary Tract Carcinoma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ARID1A
ARID1A Loss
ARID1A Mutation
ATM
ATM Loss
ATM Mutation
ATR
ATR Loss
ATR Mutation
BARD1
BARD1 Loss
BARD1 Mutation
BRCA1
BRCA1 Loss
BRCA1 Mutation
BRCA2
BRCA2 Loss
BRCA2 Mutation
BRIP1
BRIP1 Loss

BRIP1 Mutation
C11orf30
C11orf30 Mutation
CDK12
CDK12 Loss
CDK12 Mutation
CHEK1
CHEK1 Loss
CHEK1 Mutation
CHEK2

CHEK2 Loss
CHEK2 Mutation
Deficient DNA Mismatch Repair (dMMR)
ERBB2
ERBB2 Amplification
ERBB2 Mutation (somatic)
FANCA
FANCA Loss
FANCA Mutation
FANCB

FANCB Loss
FANCB Mutation
FANCC
FANCC Loss
FANCC Mutation
FANCD2
FANCD2 Loss
FANCD2 Mutation
FANCE
FANCE Loss

FANCE Mutation
FANCF
FANCF Loss
FANCF Mutation
FANCG
FANCG Loss
FANCG Mutation
FANCI
FANCI Loss
FANCI Mutation

FANCL
FANCL Loss
FANCL Mutation
FANCM
FANCM Loss
FANCM Mutation
HER2 Deficient Expression
HER2 Equivocal
HER2 Expression
HER2 Negative

HER2 Overexpression
HER2 Positive
MCPH1
MCPH1 Loss
MCPH1 Mutation
MLH1 Deficient Expression
MRE11A
MRE11A Loss
MRE11A Mutation
MSH2 Deficient Expression

MSH6 Deficient Expression
MSI-High
NBN
NBN Loss
NBN Mutation
NTRK1
NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3

NTRK3 Fusion
PALB2
PALB2 Loss
PALB2 Mutation
PD-L1 Expression (CPS >= 1)
PMS2 Deficient Expression
PTEN
PTEN Loss
PTEN Mutation
RAD50

RAD50 Loss
RAD50 Mutation
RAD51
RAD51 Loss
RAD51 Mutation
RAD51B
RAD51B Loss
RAD51B Mutation
RAD51C
RAD51C Loss

RAD51C Mutation
RAD51D
RAD51D Loss
RAD51D Mutation
RAD54L
RAD54L Loss
RAD54L Mutation
SLX4
SLX4 Loss
SLX4 Mutation

Overview

NCI Definition: A carcinoma arising from the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, or gallbladder. [1]

Biliary tract carcinomas most frequently harbor alterations in TP53, KRAS, CDKN2A, ARID1A, and IDH1 [2].

Most Commonly Altered Genes in Biliary Tract Carcinoma

TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in biliary tract carcinoma [2].

Top Alterations in Biliary Tract Carcinoma

Clinical Trials

View Clinical Trials for Biliary Tract Carcinoma

There are 34 clinical trials for biliary tract carcinoma, of which 30 are open and 4 are completed or closed. Of the trials that contain biliary tract carcinoma as an inclusion criterion, 6 are phase 1 (4 open), 4 are phase 1/phase 2 (4 open), 22 are phase 2 (20 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).

ERBB2, HER2, and Deficient are the most frequent gene inclusion criteria for biliary tract carcinoma clinical trials [3].

Trials Investigating Biliary Tract Carcinoma by Gene and Recruiting Status

Cisplatin, gemcitabine, and nivolumab are the most common interventions in biliary tract carcinoma clinical trials.

Drugs Being Investigated in Biliary Tract Carcinoma Trials by Recruiting Status

Significant Genes in Biliary Tract Carcinoma

ALK +

ALK is altered in 1.35% of biliary tract carcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ARID1A +

ARID1A is altered in 18.58% of biliary tract carcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM +

ATM is altered in 5.88% of biliary tract carcinoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR +

ATR is altered in 2.53% of biliary tract carcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 +

BARD1 is altered in 1.17% of biliary tract carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is altered in 4.57% of biliary tract carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 +

BRCA1 is altered in 1.7% of biliary tract carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 +

BRCA2 is altered in 4.12% of biliary tract carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRIP1 +

BRIP1 is altered in 0.62% of biliary tract carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

C11ORF30 +

C11orf30 is altered in 0.34% of biliary tract carcinoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 +

CCNE1 is altered in 2.27% of biliary tract carcinoma patients [2].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCNE2 +

CCNE2 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE2 status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD274 +

CD274 is altered in 0.56% of biliary tract carcinoma patients [2].

CD274 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 +

CDK12 is altered in 3.05% of biliary tract carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK1 +

CHEK1 is altered in 0.47% of biliary tract carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 +

CHEK2 is altered in 0.79% of biliary tract carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is altered in 2.58% of biliary tract carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is altered in 5.41% of biliary tract carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 6 clinical trials for biliary tract carcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (5 open) [3].

FANCA +

FANCA is altered in 1.82% of biliary tract carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCB +

FANCB is altered in 2.33% of biliary tract carcinoma patients [2].

FANCB is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCC +

FANCC is altered in 0.35% of biliary tract carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCD2 +

FANCD2 is altered in 3.17% of biliary tract carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCE +

FANCE is altered in 1.13% of biliary tract carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCF +

FANCF is altered in 0.85% of biliary tract carcinoma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCG +

FANCG is altered in 1.07% of biliary tract carcinoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCI +

FANCI is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCL +

FANCL is altered in 1.11% of biliary tract carcinoma patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCM +

FANCM is altered in 7.75% of biliary tract carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS +

KRAS is altered in 17.19% of biliary tract carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCL1 +

MCL1 is altered in 2.57% of biliary tract carcinoma patients [2].

MCL1 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCL1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCPH1 +

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A +

MRE11A is altered in 0.47% of biliary tract carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC +

MYC is altered in 2.65% of biliary tract carcinoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NBN +

NBN is altered in 1.5% of biliary tract carcinoma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 +

PALB2 is altered in 1.52% of biliary tract carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTCH1 +

PTCH1 is altered in 1.14% of biliary tract carcinoma patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN +

PTEN is altered in 2.58% of biliary tract carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD50 +

RAD50 is altered in 1.23% of biliary tract carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51 +

RAD51 is altered in 0.35% of biliary tract carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51B +

RAD51B is altered in 0.2% of biliary tract carcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C +

RAD51C is altered in 0.6% of biliary tract carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51D +

RAD51D is altered in 0.53% of biliary tract carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD54L +

RAD54L is altered in 0.38% of biliary tract carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 +

SLX4 is altered in 2.83% of biliary tract carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SMO +

SMO is altered in 0.83% of biliary tract carcinoma patients [2].

SMO is an inclusion eligibility criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Parent(s)

Pancreatobiliary Carcinoma

Children

Gallbladder Carcinoma and Bile Duct Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Biliary Tract Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Biliary Tract Carcinoma

Disease Details

References

About

Molecular Medicine

Content Types